Vasthera

VasThera is a Korea-based biopharmaceutical company dedicated to developing first-in-class synthetic therapeutics that reverse chronic vascular and inflammatory diseases. Using its proprietary Redoxizyme platform, VasThera creates novel peroxiredoxin (Prx) nanozyme compounds that normalize abnormal redox signaling — the root cause of a syndrome the company terms Peroxiredoxin Deficiency Syndrome (PDS) — which underlies cardiovascular diseases, pulmonary arterial hypertension, neurodegenerative diseases, and cancer. The company has received FDA Orphan Drug Designation for its lead PAH candidate and MFDS clearance for Phase 1 clinical trials.